These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Correlations between intravoxel incoherent motion diffusion-weighted MR imaging parameters and 18F-FDG PET/CT metabolic parameters in patients with vertebral bone metastases: initial experience. Park S, Yoon JK, Chung NS, Kim SH, Hwang J, Lee HY, Kwack KS. Br J Radiol; 2018 Jun; 91(1086):20170889. PubMed ID: 29509489 [Abstract] [Full Text] [Related]
48. Correlation of mean apparent diffusion coefficient (ADC) and maximal standard uptake value (SUVmax) evaluated by diffusion-weighted MRI and 18F-FDG-PET/CT in children with Hodgkin lymphoma: a feasibility study. Rosbach N, Fischer S, Koch V, Vogl TJ, Bochennek K, Lehrnbecher T, Mahmoudi S, Grünewald L, Grünwald F, Bernatz S. Radiol Oncol; 2023 Jun 01; 57(2):150-157. PubMed ID: 37341195 [Abstract] [Full Text] [Related]
49. Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients. Schiza A, Irenaeus S, Ortiz-Nieto F, Loskog A, Tötterman T, Sundin A, Ullenhag GJ, Ahlström H. Sci Rep; 2019 Dec 02; 9(1):18069. PubMed ID: 31792256 [Abstract] [Full Text] [Related]
54. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Ho KC, Lin G, Wang JJ, Lai CH, Chang CJ, Yen TC. Eur J Nucl Med Mol Imaging; 2009 Feb 02; 36(2):200-8. PubMed ID: 18779960 [Abstract] [Full Text] [Related]
55. Diagnostic Performance of Whole-Body Diffusion-Weighted Imaging Compared to PET-CT Plus Brain MRI in Staging Clinically Resectable Lung Cancer. Usuda K, Sagawa M, Maeda S, Motono N, Tanaka M, Machida Y, Matoba TM, Watanabe N, Tonami H, Ueda Y, Uramoto H. Asian Pac J Cancer Prev; 2016 Feb 02; 17(6):2775-80. PubMed ID: 27356689 [Abstract] [Full Text] [Related]
56. Anterior mediastinal solid tumours in adults: characterisation using dynamic contrast-enhanced MRI, diffusion-weighted MRI, and FDG-PET/CT. Yabuuchi H, Matsuo Y, Abe K, Baba S, Sunami S, Kamitani T, Yonezawa M, Yamasaki Y, Kawanami S, Nagao M, Okamoto T, Nakamura K, Yamamoto H, Sasaki M, Honda H. Clin Radiol; 2015 Nov 02; 70(11):1289-98. PubMed ID: 26272529 [Abstract] [Full Text] [Related]
57. Comparison of FDG PET/MRI and FDG PET/CT in Pediatric Oncology in Terms of Anatomic Correlation of FDG-positive Lesions. Uslu-Beşli L, Atay Kapucu LÖ, Karadeniz C, Akdemir ÜÖ, Pinarli FG, Aydos U, Okur A, Kaya Z, Samanci C, Karabacak NI. J Pediatr Hematol Oncol; 2019 Oct 02; 41(7):542-550. PubMed ID: 30933019 [Abstract] [Full Text] [Related]
58. No correlation between glucose metabolism and apparent diffusion coefficient in diffuse large B-cell lymphoma: a PET/CT and DW-MRI study. Wu X, Korkola P, Pertovaara H, Eskola H, Järvenpää R, Kellokumpu-Lehtinen PL. Eur J Radiol; 2011 Aug 02; 79(2):e117-21. PubMed ID: 21596501 [Abstract] [Full Text] [Related]
59. 18F-FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma. Eschbach RS, Kazmierczak PM, Heimer MM, Todica A, Hirner-Eppeneder H, Schneider MJ, Keinrath G, Solyanik O, Olivier J, Kunz WG, Reiser MF, Bartenstein P, Ricke J, Cyran CC. Cancer Imaging; 2018 Jan 18; 18(1):2. PubMed ID: 29347968 [Abstract] [Full Text] [Related]